|1.||Bachurin, Sergey O: 7 articles (01/2013 - 05/2003)|
|2.||Buchman, Vladimir L: 5 articles (01/2013 - 07/2009)|
|3.||Steele, J W: 3 articles (08/2013 - 01/2013)|
|4.||Martins, R N: 3 articles (08/2013 - 01/2013)|
|5.||Gandy, S: 3 articles (08/2013 - 01/2013)|
|6.||Ninkina, Natalia: 3 articles (01/2013 - 07/2009)|
|7.||Bezprozvanny, Ilya: 3 articles (10/2010 - 01/2008)|
|8.||Jordán, Joaquín: 2 articles (01/2015 - 01/2014)|
|9.||Cano-Cuenca, Nieves: 2 articles (01/2015 - 01/2014)|
|10.||Ju, S: 2 articles (08/2013 - 08/2013)|
|1.||Alzheimer Disease (Alzheimer's Disease)
07/19/2008 - "Dimebon was safe, well tolerated, and significantly improved the clinical course of patients with mild-to-moderate Alzheimer's disease."
03/01/2011 - "Dimebon was originally introduced as an antihistamine and subsequently investigated as a possible therapeutic for a variety of disorders, including Alzheimer's disease. "
07/19/2008 - "We assessed the safety, tolerability, and efficacy of dimebon in the treatment of patients with mild-to-moderate Alzheimer's disease. "
08/25/2011 - "However, the ability of latrepirdine to improve cognition in Alzheimer's disease (AD) is controversial due to a discrepancy between the positive signal reported in the multi-site phase II clinical trial where latrepirdine met all primary and secondary endpoints [Doody et al. (2008) Lancet 372:207-215], and the subsequent null effect observed in a multicenter, phase III trial. "
01/01/2011 - "Collectively, our preclinical studies using the TgCRND8 AD mouse model demonstrated that dimebon might have some beneficial effect in improving cognitive function independent of Alzheimer's disease-type Aβ-related mechanisms or global energy metabolism in the brain. "
|2.||Huntington Disease (Huntington's Disease)
10/01/2010 - "Extremely promising results were obtained in a double-blind, placebo-controlled, phase II AD trial in 183 patients; however, a phase II trial of Dimebon in 91 Huntington's disease patients was much less successful. "
01/01/2013 - "A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease."
02/01/2010 - "A randomized, placebo-controlled trial of latrepirdine in Huntington disease."
01/01/2013 - "CONCLUSION In patients with mild to moderate Huntington disease and cognitive impairment, treatment with latrepirdine for 6 months was safe and well tolerated but did not improve cognition or global function relative to placebo. "
01/01/2013 - "OBJECTIVE To determine the effect of latrepirdine on cognition and global function in patients with mild to moderate Huntington disease. "
|4.||Frontotemporal Lobar Degeneration (Semantic Dementia)
|2.||protein TDP-43 (TDP-43)
|3.||Methylene Blue (Methylthioninium Chloride)
|4.||Growth Hormone (Somatotropin)
|6.||TNFR-Fc fusion protein (etanercept)
|9.||Amyloid (Amyloid Fibrils)
|10.||Glutamic Acid (Glutamate)
|1.||Activities of Daily Living (ADL)